Skip to main content
Premium Trial:

Request an Annual Quote

Open Access Stigma

At his Open and Shut? blog, Richard Poynder addresses the question of quality in open access journals -- that is, the concern among many scientists that OA journals tend to be lower-quality than traditional journals. Many open access journals are new, and it can take awhile for them to ramp up their impact factors. "If some OA journals appear to be of lower quality than their [traditional] counterparts, this may simply be a function of their youth, and say very little about their intrinsic value," Poynder writes. He adds, "For the foreseeable future, therefore, sceptical voices will surely continue to argue that OA journals lack quality control, and so are best avoided."

 

The Scan

Could Cost Billions

NBC News reports that the new Alzheimer's disease drug from Biogen could cost Medicare in the US billions of dollars.

Not Quite Sent

The Biden Administration likely won't meet its goal of sending 80 million SARS-CoV-2 vaccine doses abroad by the end of the month, according to the Washington Post.

DTC Regulation Proposals

A new report calls on UK policymakers to review direct-to-consumer genetic testing regulations, the Independent reports.

PNAS Papers on Mosquito MicroRNAs, Acute Kidney Injury, Trichothiodystrophy

In PNAS this week: microRNAs involved in Aedes aegypti reproduction, proximal tubule cell response to kidney injury, and more.